Microanalysis Spółka z Ograniczoną Odpowiedzialnością (KRS 0000762520, NIP 7010896556) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. MICROANALYSIS operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 13, 2018. MICROANALYSIS's most recently reported net revenue was 5.7 K PLN for 2024.
Negative equity
Negative equity in 2 of 6 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Microanalysis
Identity
- Name
- Microanalysis Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 13, 2018
- Registry status as of
- January 9, 2026
- Latest entry
- January 8, 2026
- Founding act
- 08.11.2018 R., NOTARIUSZ JOLANTA BAREJ, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 11834/2018
Articles of association history (2)
- November 8, 2018: 08.11.2018 R., NOTARIUSZ JOLANTA BAREJ, KANCELARIA NOTARIALNA W WARSZAWIE, REP. A NR 11834/2018
- March 25, 2021: 25.03.2021 R., REP.A NR 3865/2021, NOTARIUSZ SŁAWOMIR WIŚNIEWSKI, KANCELARIA NOTARIALNA W WARSZAWIE, ZMIENIONO ZAPISY W UMOWIE SPÓŁKI: §8 UST.1, §9 UST.1, W §13 PO UST.7 DODAJE SIĘ UST.8-11, §17, §18, §21 UST.4, §21 UST.5, W §21 PO UST.5 DODAJE SIĘ UST.6
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
Other activities
Address and contact
- Address
- UL. BARSKA, 7/9, 9, 02-315, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWA
- CONTACT@MICROANALYSIS.PL
- Website
- MICROANALYSIS.PL
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Microanalysis
Credibility rating
1 / 100
Very poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
36
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/7 yrs
Board changes
2
2/7 yrs
PKD changes
0
0/7 yrs
Name changes
0
0/7 yrs
Data from 7 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: E (1/100)
Trend: deteriorating (-39.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2019–2024
Current: 67.72 PLN
Safe: 6.77 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Microanalysis
Founded
December 13, 2018
7 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
10.3 K PLN
205 shares total
Shareholders
4
shareholders
Board
2 people
Filed years
6 years
2019–2024 · profitable: 2/6
Registry entries
13
latest: January 8, 2026
Risk signals
Revenue
5.7 K PLN
2024
Net profit
-145.8 K PLN
2024
Assets
82.1 K PLN
2024
Equity
-290.0 K PLN
2024
EBITDA
-142.4 K PLN
2024
Companies in the same location
EU Funds
Projects co-financed by the European Union for Microanalysis - total value, EU contribution and the company's largest awards.
Projects
1
EU co-financing
5.9 M PLN
Total project value
8.8 M PLN
Eligible spending
8.8 M PLN
Funds
Operational programmes
- Program Operacyjny Inteligentny Rozwój
Largest projects
Top 1 by EU co-financing
| Project | Fund | EU co-financing | Value | Rate | Period |
|---|---|---|---|---|---|
Innowacyjny chemiczny analizator dializatu, umożliwiający personalizację zabiegu dializy |
Public procurement
Trademarks
Reviews
Rate business credibility - Microanalysis.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
